Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis

Journal of Interferon and Cytokine Research

Volumn 30, Issue 10, 2010, Pages 727-732

  Vandenbroeck, Koen ^a,b   Comabella, Manuel ^c  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b BASQUE FOUNDATION FOR SCIENCE   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CATHEPSIN S; GLUTAMATE RECEPTOR 3; GLYPICAN; INTERFERON REGULATORY FACTOR 4; INTERFERON REGULATORY FACTOR 9; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR BETA; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE TYK2; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN;

ALLELE; DRUG RECEPTOR BINDING; GENOME ANALYSIS; GENOTYPE; HUMAN; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYNAPTIC TRANSMISSION; TREATMENT RESPONSE;

HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77957333843     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2010.0085     Document Type: Review

References (43)

1. Baranzini SE, Mousavi P, Rio J., Caillier SJ, Stillman A, Villoslada P, Wyatt M.M., Comabella M., Greller LD, Somogyi R, Montalban X, Oksenberg JR. 2005. Transcription-based prediction of response to IFNbeta using supervised computational methods. PLoS Biol 3:e2.
2. Byun E, Caillier SJ, Montalban X, Villoslada P., Fernández O, Brassat D., Comabella M, Wang J, Barcellos LF, Baranzini SE, Oksenberg JR. 2008. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol '65:337-344.
3. Cénit M.D., Blanco-Kelly F, de las Heras V, Bartolomé M, de la Concha EG, Urcelay E, Arroyo R, Martínez A. 2009. Glypican 5 is an interferon-beta response gene: a replication study. Mult Scler '15:913-917.
4. Cohen JA, Cutter GR, Fischer J.S., Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock A.W., Rudick RA, Simon JH, Simonian NA, Tsao EC, Whitaker JN; IMPACT Investigators. 2002. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology '59:679-687.
5. Comabella M, Craig DW, Morcillo-Suárez C, Río J, Navarro A, Fernández M, Martin R, Montalban X. 2009a. Genome-wide scan of 500,000 single nucleotide polymorphisms in re-sponders and non-responders to interferon-beta in multiple sclerosis. Arch Neurol '66:972-978.
6. Comabella M, Fernández-Arquero M, Río J, Guinea A, Fernández M, Cenit MC, de la Concha EG, Montalban X. 2009b. HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis. J Neuroimmunol '210:116-119.
7. Comabella M, Lünemann JD, Río J, Sánchez A, López C, Julià E, Fernández M, Nonell L, Camiña-Tato M, Deisenhammer F, Caballero E, Tortola MT, Prinz M, Montalban X, Martin R. 2009c. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 132(PART 12):3353-3365.
8. Comi G, Filippi M, Barkhof F., Durelli L, Edan G, Fernández O, Hartung H., Seeldrayers P, Sørensen PS, Rovaris M, Martinelli V, Hommes OR; Early Treatment of Multiple Sclerosis Study Group. 2001. Effect of early interferon treatment on the conversion to definite multiple sclerosis; a randomized study. Lancet '357:1576-1582.
9. Cunningham S, Graham C, Hutchinson M., Droogan A, O'Rourke K, Patterson C, McDonnell G., Hawkins S, Vandenbroeck K. 2005. Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes. Clin Pharmacol Ther '78:635-646.
10. European Study Group on Interferon Beta-1b in Secondary Progressive MS. 1998. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet '352:1491-1497.
11. Fernández O., Fernández V, Mayorga C., Guerrero M, León A, Tamayo J.A., Alonso A., Romero F, Leyva L, Alonso A, Luque G, de Ramon E. 2005. HLA class II and response to interferon-beta in multiple sclerosis. Acta Neurol Scand '112:391-394.
12. Ge D, Fellay J, Thompson A.J., Simon JS, Shianna KV, Urban TJ, Heinzen E.L., Qiu P., Bertelsen AH, Muir AJ, Sulkowski M, Hutchinson JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature '461:399-401.
13. Jacobs LD, Beck RW, Simon J.H., Kinkel RP, Brownscheidle CM, Murray TJ, Simonian N.A., Slasor PJ, Sandrock AW. 2000. Intramuscular interferon beta 1a therapy initiated during a first demyelinating vent in multiple sclerosis. CHAMPS Study Group. N Engl J Med '343:898-904.
14. Jacobs LD, Cookfair DL, Rudick R.A., Herndon RM, Richert JR, Salazar AM, Fischer J.S., Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brown-scheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, and others. 1996. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol '39:285-294.
15. Kappos L, Polman CH, Freedman M.S., Edan G., Hartung HP, Miller DH, Montalban X, Barkhof F., Bauer L, Jakobs P, Pohl C, Sandbrink R. 2006. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology '67: 1242-1249.
16. Krumbholz M, Faber H, Steinmeyer F., Hoffmann LA, Kümpfel T, Pellkofer H., Derfuss T, Ionescu C, Starck M, Hafner C, Hohlfeld R, Meinl E. 2008. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 131(PART 6):1455-1463.
17. Leyva L, Fernández O, Fedetz M., Blanco E, Fernandez VE, Oliver B, Leon A., Pinto-Medel MJ, Mayorga C, Guerrero M, Luque G, Alcina A, Matesanz F. 2005. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol '163:165-171.
18. Lublin FD, Reingold SC 1996. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology '46:907-911.
19. Martínez A., de las Heras V, Mas Fontao A, Bartolomé M, de la Concha EG, Urcelay E, Arroyo R.2006. An IFNG polymorphism is associated with interferon-beta response in Spanish MS patients. J Neuroimmunol '173:196-199.
20. Mayer ML, Armstrong N. 2004. Structure and function of glutamate receptor ion channels. Annu Rev Physiol '66:161-181.
21. Minagar A, Adamashvili I, Kelley R.E., Gonzalez-Toledo E, McLarty J, Smith SJ 2007. Saliva soluble HLA as a potential marker of response to interferon-beta1a in multiple sclerosis: a preliminary study. J Neuroinflamm 4:16.
22. O'Doherty C., Favorov A, Heggarty S., Graham C, Favorova O, Ochs M., Hawkins S, Hutchinson M, Vandenbroeck K. 2009. Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients. Pharmacogenomics '10:1177-1186.
23. O'Doherty C., Villoslada P, Vandenbroeck K. 2007. Pharmacogenomics of type I interferon therapy: a survey of response-modifying genes. Cytokine Growth Factor Rev '18:211-222.
24. Panitch H, Miller A, Paty D., Weinshenker B. North American Study Group on Interferon Beta-1b in Secondary Progressive MS. 2004. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology '63:1788-1795. (Pubitemid 39532370)
25. Pitt D, Werner P, Raine CS 2000. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med '6:67-70.
26. Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis (PRISMS) Study Group. 1998. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet '352:1498-1504.
27. Río J., Nos C, Tintoré M, Borrás C, Galán I, Comabella M, Montalban X. 2002. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol '52:400-406.
28. Sánchez-Gómez MV, Matute C. 1999. AMPA and kainate receptors each mediate excitotoxicity in oligodendroglial cultures. Neurobiol Dis '6:475-485.
29. Seeburg PH. 1993. The TINS/TiPS Lecture. The molecular biology of mammalian glutamate receptor channels. Trends Neurosci '16:359-365.
30. Soilu-Hanninen M., Laaksonen M, Hanninen A., Eralinna JP, Panelius M. 2005. Downregulation of VLA-4 on T cells as a marker of long term treatment response to interferon beta-1a in MS. J Neuroimmunol 167:175-182.
31. Sospedra M, Martin R. 2005. Immunology of multiple sclerosis. Annu Rev Immunol '23:683-747.
32. Sriram U, Barcellos LF, Villoslada P, Rio J., Baranzini SE, Caillier S, Stillman A, Hauser S.L., Montalban X., Oksenberg JR. 2003. Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes Immun '4:147-152.
33. Steinhäuser C., Gallo V. 1996. News on glutamate receptors in glial cells. Trends Neurosci '19:339-345.
34. Suppiah V, Moldovan M, Ahlenstiel G., Berg T, Weltman M, Abate M.L., Bassendine M., Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. 2009. IL28B is associated with response to chronic hepatitis Cinterferon-alpha and ribavirin therapy. Nat Genet '41:1100-1104.
35. Tanaka Y, Nishida N, Sugiyama M., Kurosaki M, Matsuura K, Sakamoto N., Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109.
36. The Interferon β Multiple Sclerosis Study Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology '43:655-661.
37. Vandenbroeck K, Comabella M, Tolosa E., Goertsches R, Brassat D, Hintzen R., Infante-Duarte C, Favorov A, Escorza S, Palacios R, Oksenberg JR, Villoslada P. 2009. United Europeans for development of pharmacogenomics in multiple sclerosis network. Pharmacogenomics '10:885-894.
38. Vandenbroeck K, Matute C. 2008. Pharmacogenomics of the response to IFN-β in multiple sclerosis: ramifications from the first genome-wide screen. Pharmacogenomics '9:639-645.
39. Villoslada P, Barcellos LF, Rio J, Begovich A.B., Tintore M., Sastre-Garriga J, Baranzini SE, Casquero P, Hauser S.L., Montalban X., Oksenberg JR. 2002. The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-beta. J Neuroimmunol '130:194-201.
40. Wandinger KP, Lunemann JD, Wengert O, Bellmann-Strobl J, Aktas O., Weber A, Grundström E, Ehrlich S., Wernecke KD, Volk HD, Zipp F. 2003. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet '361: 2036-2043.
41. Weinstock-Guttman B., Tamano-Blanco M, Bhasi K., Zivadinov R, Ramanathan M. 2007. Pharmacogenetics of MXA SNPs in interferon-β treated multiple sclerosis patients. J Neuroimmunol '182:236-239.
42. Wergeland S, Beiske A, Nyland H., Hovdal H, Jensen D, Larsen J.P., Maroy TH, Smievoll AI, Vedeler CA, Myhr KM. 2005. IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. Eur J Neurol '12:171-175.
43. Werner P, Pitt D, Raine CS 2001. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligoden-drocyte and axonal damage. Ann Neurol '50:169-180.